Anzeige
Mehr »
Login
Sonntag, 18.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Hohe Umsätze deuten nächste Kurs-Explosion an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCUH ISIN: SE0014855029 Ticker-Symbol: 8IM1 
Tradegate
16.04.21
20:08 Uhr
12,580 Euro
-0,660
-4,98 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMPLANTICA AG SDR Chart 1 Jahr
5-Tage-Chart
IMPLANTICA AG SDR 5-Tage-Chart
RealtimeGeldBriefZeit
12,44012,66016.04.
PR Newswire
366 Leser
Artikel bewerten:
(2)

Implantica announces a milestone achieved for its implantable medical device RefluxStop

STOCKHOLM, March 23, 2021 /PRNewswire/ -- Implantica AG (publ) today announces that one of the largest hospitals in Europe, University Hospital AKH Vienna, will soon commence a study of RefluxStop with 25-30 reflux patients, conducted under the direction of Prof. Dr. med. Sebastian Schoppmann.

"We are very pleased that one of the most prominent anti-reflux surgeons, Prof. Schoppmann, will perform the RefluxStop procedure, and we are looking forward to begin cooperating with one of the leading anti-reflux surgeons in Europe" said Peter Forsell, CEO of Implantica.

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on March 23, 2021 at 08:00 a.m. CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-announces-a-milestone-achieved-for-its-implantable-medical-device-refluxstop-,c3312007

The following files are available for download:

https://mb.cision.com/Main/19732/3312007/1391007.pdf

Implantica announces a milestone achieved for its implantable medical device RefluxStop'

IMPLANTICA-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.